Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q04828
UPID:
AK1C1_HUMAN
Alternative names:
20-alpha-hydroxysteroid dehydrogenase; Chlordecone reductase homolog HAKRC; Dihydrodiol dehydrogenase 1; High-affinity hepatic bile acid-binding protein
Alternative UPACC:
Q04828; P52896; Q5SR15; Q7M4N2; Q9UCX2
Background:
Aldo-keto reductase family 1 member C1, known by alternative names such as 20-alpha-hydroxysteroid dehydrogenase and High-affinity hepatic bile acid-binding protein, plays a crucial role in the metabolism of hormones including estrogens and androgens. It catalyzes the reduction of ketosteroids to hydroxysteroids, displaying broad positional specificity and affinity for bile acids.
Therapeutic significance:
Understanding the role of Aldo-keto reductase family 1 member C1 could open doors to potential therapeutic strategies.